De la Cruz J P, Pavia J, Garcia-Arnes J, Sanchez de la Cuesta F
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
Eur J Haematol. 1988 Mar;40(3):232-6. doi: 10.1111/j.1600-0609.1988.tb00829.x.
A study was made on the inhibitory effect of triflusal (600 mg/d X 15) and acetylsalicylic acid (ASA, 400 mg/d X 15) on platelet aggregation in whole blood (WB) and platelet-rich plasma (PRP) induced by ADP (2.5 mumol/l), adrenaline (50 mumol/l), collagen (1 microgram/ml) and arachidonic acid (0.8 mmol/l), in 30 insulin-dependent diabetic patients without vascular complications. Determination was also made of the serum levels of thromboxane B2 (TxB2) and of the plasma levels of 6-keto-PGF1-alpha and of beta-thromboglobulin (B-TG). Both drugs exhibited higher inhibitory effects in WB than in PRP. In WB, a significant difference between triflusal and ASA was observed against ADP-induced aggregation (67% and 46% inhibition respectively, p less than 0.01). Both drugs strongly inhibit the formation of TxB2 in serum (85% and 99%, respectively). Triflusal does not significantly change the plasma levels of 6-keto-PGF1-alpha; ASA, by contrast, causes reduction of over 95% in those plasma levels. The plasma levels of B-TG were not modified by either of the drugs.
对30例无血管并发症的胰岛素依赖型糖尿病患者,研究了曲氟尿苷(600毫克/天×15天)和乙酰水杨酸(阿司匹林,400毫克/天×15天)对由二磷酸腺苷(2.5微摩尔/升)、肾上腺素(50微摩尔/升)、胶原(1微克/毫升)和花生四烯酸(0.8毫摩尔/升)诱导的全血(WB)和富血小板血浆(PRP)中血小板聚集的抑制作用。还测定了血栓素B2(TxB2)的血清水平、6-酮-前列环素F1α和β-血小板球蛋白(B-TG)的血浆水平。两种药物在全血中的抑制作用均高于富血小板血浆。在全血中,观察到曲氟尿苷和阿司匹林在抑制二磷酸腺苷诱导的聚集方面存在显著差异(分别为67%和46%的抑制率,p<0.01)。两种药物均强烈抑制血清中血栓素B2的形成(分别为85%和99%)。曲氟尿苷不会显著改变6-酮-前列环素F1α的血浆水平;相比之下,阿司匹林会使这些血浆水平降低超过95%。两种药物均未改变β-血小板球蛋白的血浆水平。